Immunologic and biochemical factors of coincident celiac disease and type 1 diabetes mellitus in children

Pediatric Research

Volumn 64, Issue 6, 2008, Pages 677-681

  Myśliwtec, Małgorzata ^a   Balcerska, Anna ^a   Zorena, Katarzyna ^a   Myśliwska, Jolanta ^a   Wiśniewski, Piotr ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ENDOMYSIUM ANTIBODY; GLIADIN ANTIBODY; GLOBULIN; GLYCOSYLATED HEMOGLOBIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTOR; INTERLEUKIN 10; INTERLEUKIN 6; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; THYROID PEROXIDASE ANTIBODY; THYROTROPIN; TIREOGLOBULIN ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; AUTOIMMUNE THYROIDITIS; CELIAC DISEASE; CHILD; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FREE LIOTHYRONINE INDEX; FREE THYROXINE INDEX; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; SCHOOL CHILD; SENSITIVITY ANALYSIS; SEROLOGY;

ADOLESCENT; CELIAC DISEASE; CHILD; COMORBIDITY; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; INTERLEUKIN-10; INTERLEUKIN-6; MALE; SENSITIVITY AND SPECIFICITY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 57849090470     PISSN: 00313998     EISSN: None     Source Type: Journal    
DOI: 10.1203/PDR.0b013e318187189e     Document Type: Article

References (40)

1. Ventura A, Magazzu G, Greco L 1999 Duration of exposure to gluten and risk for autoimmune disorders in patients with celiac disease. SIGEP Study Group for Autoimmune Disorders in Celiac Disease. Gastroenterology 117:297-303
2. Not T 2001 Undiagnosed celiac disease and risk of autoimmune disorders in subjects with type 1 diabetes. Diabetologia 44:151-155
3. Myśliwiec M, Balcerska A, Stȩpiński J, Ba̧kowska A, Jȩdrzejczyk A 2006 [Prognostic factors of celiac disease occurrence in type 1 diabetes mellitus children]. Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw 12:281-285
4. Farrell RJ, Kelly CP 2002 Celiac sprue. N Engl J Med 346:180-188
5. Sumnik Z 2000 HLA-DQA1*05-DQB1*0201 positivity predisposes to celiac disease in Czech diabetic children. Acta Paediatr 89:1426-1430
6. Hanifi-Moghaddam P, Schloot NC, Kappler S, Seissler J, Kolb H 2003 An association of autoantibody status and serum cytokine levels in type 1 diabetes. Diabetes 52:1137-1142
7. Myśliwiec M, Zorena K, Balcerska A, Mysliwska J, Lipowski P, Raczyńska K 2006 The activity of N-acetyl-beta-D- glucosaminidase and tumor necrosis factor-alpha at early stage of diabetic retinopathy development in type 1 diabetes mellitus children. Clin Biochem 39:851-856
8. Myśliwiec M, Balcerska A, Zorena K, Myśliwska J, Lipowski P, Raczyńska K 2008 The role of vascular endothelial growth factor, tumor necrosis factor alpha and interleukin-6 in pathogenesis of diabetic retinopathy. Diabetes Res Clin Pract 79:141-146
9. Myśliwiec M, Balcerska A, Zorena K, Myśliwska J 2006 Serum and urinary cytokine homeostasis and renal tubular function in type 1 diabetes mellitus children. J Pediatr Endocrinol Metab 19:1421-1427
10. Zorena K, Myśliwska J, Myśliwiec M, Balcerska A, Lipowski P, Raczyńska K 2008 Interleukin 12 and tumor necrosis factor-α equilibrium is prerequisite for clinical course free from late complications in type 1 diabetes mellitus children. Scand J Immunol 67:204-208
11. American Diabetes Association 2003 Diagnosis and classification of diabetes. Diabetes Care 26:3160-3167
12. Oberhuber G, Granditsch G, Vogelsang H 1999 The histopathology of coeliac disease: time for a standardized report scheme for pathologists. Eur J Gastroenterol Hepatol 11:1185-1194
13. Ladinser B, Rossipal E, Pittschieler K 1994 Endomysium antibodies in coeliac disease: an improved method. Gut 35:776-778
14. Funda DP, Kaas A, Bock T, Tlaskalová-Hogenová H, Buschard K 1999 Gluten-free diet prevents diabetes in NOD mice. Diabetes Metab Res Rev 15:323-327
15. Hummel M, Bonifacio E, Naserke HE, Ziegler AG 2002 Elimination of dietary gluten does not reduce titers of type 1 diabetes-associated autoantibodies in high-risk subjects. Diabetes Care 25:1111-1116
16. Kostraba JN 1994 What can epidemiology tell us about the role of infant diet in the etiology of IDDM? Diabetes Care 17:87-91
17. Schram MT, Chaturvedi N, Schalkwijk C, Giorgino F, Ebeling P, Fuller JH, Stehouwer CD 2005 EURODIAB Prospective Complications Study Group: markers of inflamantion are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes. The EURODIAB Prospective Complications Study. Diabetologia 48:370-378
18. Targher G, Zenari L, Bertolini L, Muggeo M, Zoppini G 2001 Elevated levels of interleukin-6 in young adults with type 1 diabetes without clinical evidence of microvascular and macrovascular complications. Diabetes Care 24:956-957
19. Myśliwiec M, Balcerska A, Zorena K, Myśliwska J, Nowacka M, Lipowski P, Raczyńska K 2006 [Selected immunologic and biochemical risk factor of the retinopathy and nephropathy development in children with diabetes mellitus type 1]. Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw 12:269-273
20. Fabris M, Visentini D, De Re V, Picierno A, Maieron R, Cannizzaro R, Villalta D, Curcio F, De Vita S, Tonutti E 2007 Elevated B cell-activating factor of the tumor necrosis factor family in celiac disease. Scand J Gastroenterol 42:1434-1439
21. Sakly W, Bienvenu F, Peretti N, Lachaux A, Morel S, Bouvier R, Nicolino M, Bienvenu J, Spiteri A, Fabien N 2005 IgA antitransglutaminase antibodies as a tool for screening atypical forms of coeliac disease in a French at-risk paediatric population. Eur J Gastroenterol Hepatol 17:235-239
22. Garrote JA, Arranz E, Górnez-González E, Leon AJ, Farre C, Calvo C, Bernardo D, Fernández-Salazar Ł, Blanco-Quirós A 2005 IL 6, 1L-10 and TGFB1 gene polymorphisms in coeliac disease: differences between DQ2 positive and negative patients. Allergol Immunopathol (Madr) 33:245-249
23. Amin R, Murphy N, Edge J, Ahmed ML, Acerini CL, Dunger DB 2002 A longitudinal study of the effect of a gluten-free diet on glycemic control and weight gain in subjects with type 1 diabetes and celiac disease. Diabetes Care 25:1117-1122
24. Glastras SJ, Craig ME, Verge CF, Chan AK, Cusumano JM, Donaghue KC 2005 The role of autoimmunity at diagnosis of type 1 diabetesin in the development of thyroid and celiac disease and microvascular complications. Diabetes Care 28:2170-2175
25. Kaukinen K, Salmi J, Lahtela J, Siljamäki-Ojansuu U, Koivisto AM, Oksa H, Collin P 1999 No effect of gluten-free diet on the metabolic control of type 1 diabetes in patients with diabetes and celiac disease. Retrospective and controlled prospective survey. Diabetes Care 22:1747-1748
26. Morohoshi M, Fujisawa K, Uchimura I, Numano F 1995 The effect of glucose and advanced glycosylation end products on IL-6 production by human monocytem. Ann NY Acad Sci 748:562-570
27. Hansson T, Danneus A, Klareskog L 1999 Cytokine-producing cells in peripheral blood of children with coeliac disease secrete cytokines with a type 1 profile. Clin Exp Immunol 116:246-250
28. Przemiosło RT, Kontakou M, Nobili V, Ciclitira PJ 1994 Raised pro-inflammatory cytokinez interleukin 6 and tumour necrosis factor α in celiac disease mucosa detected by immunohistochemistry. Gut 35:1398-1403
29. Salvati VM, Mazzarella G, Gianfrani C, Levings MK, Stefanile R 2005 Recombinant human interleukin 10 suppresses gliadin dependent T cell activation in ex vivo cultured coeliac intestinal mucosa. Gut 54:46-53
30. Sellon RK, Tonkonogy S, Schultz M 1998 Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10 deficient mice. Infect Immun 66:5224-5231
31. Herfarth H, Scholmerich J 2002 IL-10 therapy in Crohn's disease: at the crossroads. Gut 50:146-147
32. Sandborn WJ, Targan SR 2002 Biologic therapy of inflammatory bowel disease. Gastroenterology 122:1592-1608
33. Rizzo LV, XU H, Chan CC, Wiggert B, Caspi RR 1998 IL-10 has a protective role in experimental autoimmune uveoretinitis. Int Immunol 10:807-814
34. Lugering N, Kucharzik T, Stein H 1998 IL-10 synergizes with IL-4 and IL-13 in inhibiting lysosomal enzyme secretion by human monocytes and lamina propria mononuclear cells from patients with inflammatory bowel disease. Dig Dis Sci 43:706-714
35. Fedorak RN, Gangl A, Elson CO, Rutgeerts P, Schreiber S, Wild G, Hanauer SB, Kilian A, Cohard M, LeBeaut A, Feagan B 2000 Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 119:1473-1482
36. Raddatz D, Bockemucombining double acute accenthl M, Ramadori G 2005 Quantitative measurement of cytokine mRNA in inflammatory bowel disease:relation to clinical and endoscopic activity and outcome. Eur J Gastroenterol Hepatol 17:547-557
37. Tilg H, Feichtenschlager T, Knoflach P, Petritsch W, Schocombining double acute accentft R, Vogelsang H, Reinisch W 2007 [Use of infliximab in ulcerative colitis]. Z Gastroenterol 45:907-911
38. Wewer V, Riis S, Vind 12006 Infliximab dependency in a national cohort of children with Crohn's disease. J Pediatr Gastroenterol Nutr 42:40-45
39. Colombel JF, Loftus EV Jr, Trentaine WJ, Egan LJ, Harmsen WS, Schleck CD, Zinsmeister AR, Sandborn WJ 2004 The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 126:19-31
40. Feagan BG, Sandbom WJ, Lichtenstein G, Radford-Smith G, Patel J, Innes A 2006 CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther 23:617-628